Clinical Trials in Dallas

Showing 2281-2300 of 17,468 trials

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

NCT07226778

The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

OverweightObesity

Amgen348 participantsStarted Oct 2025

Anaheim, California, United States • Daytona Beach, Florida, United States • Dallas, Texas, United States +1 more locations

COMPLETEDPhase 312 miles

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT05610280

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.

HypertriglyceridemiaCardiovascular DiseasesAtherosclerosis

Ionis Pharmaceuticals, Inc.1,478 participantsStarted Nov 2022

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Beverly Hills, California, United States +165 more locations

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Find Trials by Condition in Dallas

Amplatzer Amulet LAAO vs. NOAC

Global Registry for Endovascular Aortic Treatment (GREAT)

FX Shoulder Prospective Clinical Study

Empowering Families Project

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

ORB-021 In Patients With Advanced Solid Tumors

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Shared Decision Making to Improve Goals of Care in the ED

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma